Clinical Trial Update: Extension Study of PRX-102 for up to 60 Months [Phase 1, Phase 2]

View source ↗

Summary

Extension study update for PRX-102 in Fabry disease following Phase 1/2, with results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• PRX-102

Snippet

Sponsor: Protalix | Conditions: Fabry Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-02-08